M
Michel Farnier
Researcher at Regeneron
Publications - 105
Citations - 7627
Michel Farnier is an academic researcher from Regeneron. The author has contributed to research in topics: Alirocumab & PCSK9. The author has an hindex of 28, co-authored 105 publications receiving 4785 citations. Previous affiliations of Michel Farnier include Merck & Co. & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
TL;DR: Greater dissociation of apoB, LDL-C, and non-HDL-C targets occur following treatment with ERN/LRPT, SIMVA, and ERN /LRPT + SIMVA in patients with dyslipidemia.
Journal ArticleDOI
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials
Michel Farnier,David Marcereuil,Sophie De Niet,Jean Ducobu,Armin Steinmetz,Kjetil Retterstøl,Leszek Bryniarski,Albert Császár,Francis Vanderbist +8 more
TL;DR: The acceptable long-term safety profile of FF/PRA 160 mg/40 mg was confirmed with a low frequency of AEs of interest, comparable to that observed in the 12-week double-blind cohort and within the limitations of this database, no particular safety concern was raised.
Journal ArticleDOI
New prospects for PCSK9 inhibition
Ulf Landmesser,M. John Chapman,Jane K Stock,Pierre Amarenco,Jill J. F. Belch,Jan Borén,Michel Farnier,Brian A. Ference,Stephan Gielen,Ian D. Graham,Diederick E. Grobbee,G. Kees Hovingh,Thomas F. Lüscher,Massimo F Piepoli,Kausik K. Ray,Erik S.G. Stroes,Olov Wiklund,Stephan Windecker,José Luis Zamorano,Fausto J. Pinto,Lale Tokgozoglu,Jeroen J. Bax,Alberico L. Catapano +22 more
TL;DR: This poster presents a poster presented at the 2015 European Atherosclerosis Society Task Force meeting in Brussels, Belgium, presenting the results of a two-week study of plaque formation in the central giant cell of the immune system and its role in promoting wound healing.
Journal ArticleDOI
Corrigendum to:: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)
Ulf Landmesser,M. John Chapman,Jane K Stock,Pierre Amarenco,Jill J. F. Belch,Jan Borén,Michel Farnier,Brian A. Ference,Stephan Gielen,Ian D. Graham,Diederick E. Grobbee,G. Kees Hovingh,G. Kees Hovingh,Thomas F. Lüscher,Massimo F Piepoli,Kausik K. Ray,Erik S.G. Stroes,Olov Wiklund,Stephan Windecker,José Luis Zamorano,Fausto J. Pinto,Lale Tokgozoglu,Jeroen J. Bax,Alberico L. Catapano +23 more
Journal ArticleDOI
Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for an acute myocardial infarction: Data from the French RICO survey
Michel Farnier,Clémence Salignon-Vernay,H. Yao,Frédéric Chagué,Philippe Brunel,Maud Maza,Damien Brunet,Florence Bichat,Jean-Claude Beer,Yves Cottin,Marianne Zeller +10 more
TL;DR: In this large cohort of French individuals, FH was common in patients with MI, associated with markedly early age of MI and severity of CAD burden and limited use of preventive lipid-lowering therapy.